Our News
All the latest company news, views and insight from the Beckley Psytech team.
Beckley Psytech announces partnership with Ksana Health, building on digital strategy to deliver opt...
Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials Beckley Psytech aims to track and improve patient experience through an integrated, digitally-as... Read More
Beckley Psytech strengthens senior leadership team with appointment of Dr. Laura Trespidi as Chief D...
Dr. Trespidi brings more than 30 years’ of experience in global pharmaceutical and biotechnology companies, across clinical product development and manufacturing, from pre-clinical research through to market approvals and global product launches.
Beckley Psytech announces partnership with Empatica in latest step of digital strategy, designed to ...
Partnership will capture behavioural and physiological signals and predictive biomarkers in Beckley Psytech’s upcoming Phase 2 clinical trials. New digital strategy aims to improve patient outcomes and safety by integrating advanced digital tools i... Read More
Beckley Psytech bolsters pipeline of next-generation psychedelic medicines with research collaborati...
Beckley Psytech to collaborate with Lophora on researching New Clinical Entities (NCE’s) Broad collaboration with Lophora will further strengthen Beckley Psytech’s world class management and R&D team
Beckley Psytech to attend and present at 8th Annual LSX World Congress 2022
Beckley Psytech Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will attend the ... Read More
Beckley Psytech announces dosing of first healthy volunteers in Phase 1 clinical trial assessing saf...
Study represents continued efforts to further understand the clinical and pharmacological potential of 5-MeO-DMT. BPL-003 is Beckley Psytech’s innovative dry powder intranasal formulation of 5-MeO-DMT using FDA approved intranasal delivery devices.... Read More
Beckley Psytech to present at 32nd Annual Oppenheimer Healthcare Conference
Beckley Psytech Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will attend the ... Read More
Beckley Psytech publishes peer-reviewed paper on 5-MeO-DMT in Journal of Psychopharmacology
Literature review highlights need for further clinical exploration of 5-MeO-DMT
Beckley Psytech announces first cohort of psychotherapists have begun training for treatment resista...
Initiation of training represents key step to incorporate psychedelic-assisted psychotherapy to deliver potentially clinically meaningful improvements
Beckley Psytech applies for B Corporation status as part of its commitment to have a positive impact...
B Corporations represent a new kind of business philosophy to protect and develop the future of all stakeholders.